Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Modified stem cells offer potential pathway to treat Alzheimer's disease

  • Scientists explain how memories stick together

  • In old age, lack of emotion, interest may signal brain is shrinking

  • Book early, after work if you want to enjoy your next hotel stay

  • Intravenously administered ketamine shown to reduce symptoms of chronic post-traumatic stress disorder

  • Distracted driving among teens threatens public health and safety

  • Conceptual representation in the brain: Towards mind-reading?

  • Common links between neurodegenerative diseases identified

  • For resetting circadian rhythms, neural cooperation is key

  • Neurons in brain tune into different frequencies for different spatial memory tasks

  •